Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2029

Conditions
Prostate Cancer
Interventions
DEVICE

Vanquish System

Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.

Trial Locations (26)

10016

NYU Langone Health, New York

11222

Northwell Health- Lenox Hill Hospital, New York

14620

University of Rochester, Rochester

19004

MidLantic Urology, Bala-Cynwyd

21204

Chesapeake Urology, Baltimore

21287

Johns Hopkins, Baltimore

23462

Urology of Virginia, PLLC, Virginia Beach

27710

Duke Cancer Institute, Durham

29572

Carolina Urologic Research Center, Myrtle Beach

32216

Kasraeian Urology, Jacksonville

45212

The Urology Group, Cincinnati

48073

Corewell Health / William Beaumont University Hospital, Royal Oak

48084

Michigan Institute of Urology, Troy

53226

Medical College of Wisconsin, Milwaukee

55125

Minnesota Urology, Woodbury

55454

University of Minnesota, Minneapolis

55905

Mayo Clinic- Rochester, Rochester

60637

University of Chicago, Chicago

67226

Wichita Urology, Wichita

71111

WK Advanced Urology Specialists, Shreveport

77030

Houston Methodist Hospital and Research Institute, Houston

78240

The Urology Place, San Antonio

78745

Urology Austin, Austin

85054

Mayo Clinic- Phoenix, Phoenix

90089

University of Southern California, Los Angeles

92653

Memorial Care, Laguna Hills

Sponsors
All Listed Sponsors
lead

Francis Medical Inc.

INDUSTRY